191 related articles for article (PubMed ID: 7455583)
1. Behaviour of uricemia in hyperlipoproteinemic subjects.
Zdrenghea D; Marta D; Constantinescu M; Cucuianu M
Med Interne; 1980; 18(4):385-90. PubMed ID: 7455583
[TBL] [Abstract][Full Text] [Related]
2. Increased level of the complement C3 protein in endogenous hypertriglyceridemia.
Uza G; Cristea A; Cucuianu MP
J Clin Lab Immunol; 1982 Jun; 8(2):101-5. PubMed ID: 7108936
[TBL] [Abstract][Full Text] [Related]
3. Behaviour of platelet adhesiveness and of dilute clot blood lysis time in hyperlipoproteinemic subjects.
Zdrenghea D; Stef C; Cucuianu M; Vlaicu R
Med Interne; 1979; 17(3):273-7. PubMed ID: 504931
[No Abstract] [Full Text] [Related]
4. [Effect of halofenate on triglyceride and uric acid levels, coagulation and platelet behaviour in patients with hyperlipoproteinemia type IV and hyperuricemia (author's transl)].
Kuntzen O; Hehl FJ; Walter E; Zimmermann R
Arzneimittelforschung; 1978; 28(12):2349-52. PubMed ID: 227420
[TBL] [Abstract][Full Text] [Related]
5. [Serum uric acid levels in disorders of the rheumatic type].
Bosmanský K; Trnavský K
Z Rheumatol; 1984; 43(2):59-62. PubMed ID: 6610259
[TBL] [Abstract][Full Text] [Related]
6. Lipid peroxidative damage in the erythrocytes and elevation of serum LDL-cholesterol, apolipoprotein-B, ferritin and uric acid with age and in coronary heart disease patients.
El-Gebali HH; Tahir SA; Haider SS; El-Fakhri MM
Saudi Med J; 2000 Feb; 21(2):184-9. PubMed ID: 11533779
[TBL] [Abstract][Full Text] [Related]
7. Increased plasma level of clotting factors VII and X in hyperlipoproteinemia.
Cucuianu M; Popescu TA; Roman S; Bedeleanu D; Păiş R
Med Interne; 1985; 23(1):37-43. PubMed ID: 3992146
[TBL] [Abstract][Full Text] [Related]
8. Hemorrheologic abnormalities in defined primary dyslipoproteinemias with both high and low atherosclerotic risks.
Otto C; Ritter MM; Richter WO; Minkenberg R; Schwandt P
Metabolism; 2001 Feb; 50(2):166-70. PubMed ID: 11229424
[TBL] [Abstract][Full Text] [Related]
9. [Uric acid levels of the serum of healthy persons and patients with various rheumatic diseases].
Bośmanský K; Ondrasík M
Ter Arkh; 1987; 59(4):22-5. PubMed ID: 3495897
[TBL] [Abstract][Full Text] [Related]
10. [Hyperlipoprotein phenotypes as risk factors in ischemic cardiopathy. II. Clinical aspects].
Walter-Rosianu A
Rev Pediatr Obstet Ginecol Pediatr; 1984; 33(2):145-60. PubMed ID: 6429817
[No Abstract] [Full Text] [Related]
11. Serum uric acid and insulin secretion in diabetes mellitus.
Sinagra D; Scarpitta AM; Bonaventura V; Greco D; Perrone P; Picone G; Brigandì M
Riv Eur Sci Med Farmacol; 1996; 18(4):173-7. PubMed ID: 9177618
[TBL] [Abstract][Full Text] [Related]
12. [Biochemical diagnosis of hereditary hyperlipoproteinemias].
Tvorogova MG; Rozhkova TA; Alidzhanova KhG; Semenova OA; Sobolev AV; Kukharchuk VV; Titov VN
Ter Arkh; 1998; 70(4):9-15. PubMed ID: 9612894
[TBL] [Abstract][Full Text] [Related]
13. [Uricemia in diabetes mellitus: variations and significance].
Duţu A; Hîncu N; Hoinărescu E
Rev Med Interna Neurol Psihiatr Neurochir Dermatovenerol Med Interna; 1976; 28(3):227-34. PubMed ID: 7831
[No Abstract] [Full Text] [Related]
14. [Platelet aggregation in hyperlipoproteinemias].
Calabrese S; Da Col PG; Giansante C; Morgante O; Cattin L
Minerva Med; 1982 May; 73(22):1541-6. PubMed ID: 7088380
[TBL] [Abstract][Full Text] [Related]
15. [Hyperlipoproteinemias as risk factors for ischemic cardiopathy: new diagnostic possibilities].
Gaddi A; Scaramuzzino G; Benassi MS; Aluigi L; Ceredi C; Albertazzi I; Suffritti G; Descovich GC
Boll Soc Ital Cardiol; 1978; 23(9):1537-44. PubMed ID: 553627
[No Abstract] [Full Text] [Related]
16. [Correlation of blood uric acid changes with hyperlipoproteinemia in diabetes mellitus].
Duţu A; Hincu N; Motocu M; Hoinărescu E; Tecuceanu R
Rev Med Interna Neurol Psihiatr Neurochir Dermatovenerol Med Interna; 1976; 28(6):455-8. PubMed ID: 14385
[No Abstract] [Full Text] [Related]
17. [Beta 2 glycoprotein I analysis in patients with hyperlipoproteinemia, arteriosclerotic occlusive disease and diabetes mellitus].
Müller G; Biering A; Lux E; Richter V
Z Gesamte Inn Med; 1983 May; 38(10):282-4. PubMed ID: 6613192
[TBL] [Abstract][Full Text] [Related]
18. [Therapy of hyperlipoproteinemia type IIa, IIb and IV with Etofibrate retard].
Schwartzkopff W; Schilling A; Calder D
Med Welt; 1980 Apr; 31(14):515-20. PubMed ID: 7374415
[No Abstract] [Full Text] [Related]
19. [Effect of acipimox on diabetes mellitus-associated hyperlipoproteinemia].
Paragh G; Balogh Z; Boda J; Mohácsi A; Juhász A; Leövey A
Orv Hetil; 1993 Jan; 134(3):121-4. PubMed ID: 8421622
[TBL] [Abstract][Full Text] [Related]
20. Increased values of antipyrine clearance in type IV hyperlipoproteinemia.
Bedeleanu D; Trif I; Lötsch JC; Cucuianu MP
Med Interne; 1986; 24(3):183-90. PubMed ID: 3775212
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
